SEATTLE — Suprachoroidal axitinib had an “excellent” safety profile at all doses in the treatment of wet age-related macular degeneration, with early signs of durability and reduction in treatment burden, a speaker said here.
“Tyrosine kinase inhibitors are an exciting new molecular target in the treatment of neovascular AMD,” Rahul N. Khurana, MD, said at the American Society of Retina Specialists annual meeting. “Our current treatments target the extracellular VEGF-A and -B, which have excellent efficacy. However, there can be an upregulation of VEGF-C and